Search
Dolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigational[L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named … [A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013.
Mixtures: TRIUMEQ® 50 MG / 600 MG / 300 MG, TRIUMEQ 50 MG/600 MG/300 MG FILM KAPLI TABLET,90 FILM KAPLI TABLETCategories: MATE 1 Inhibitors, P-glycoprotein substratesAbatacept
go.drugbank.com/drugs/DB01281ApprovedInvestigational[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of two homologous polypeptide chains of 357 amino acids each … Although approved for the treatment of rheumatoid arthritis, Repligen has entered a slightly different formulation of CTLA4-Ig into clinical trials (RG2077).
Categories: Selective T Cell Costimulation ModulatorProducts: ORENCIA® SOLUCION INYECTABLE PARA ADMINISTRACION SUBCUTÁNEA 125 MG/ML, ORENCIA® 250 MG - POLVO LIOFILIZADO PARA SOLUCIÓN INYECTABLE INTRAVENOSACefprozil
go.drugbank.com/drugs/DB01150ApprovedInvestigationalCefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
Categories: Heterocyclic Compounds, 2-RingProducts: CEFNOR 250 MG EFERVESAN TABLET, 20 ADET, PREFIX 250 MG FILM TABLET, 20 ADETSimethicone
go.drugbank.com/drugs/DB09512ApprovedInvestigationalSimethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination. … [A228308] It has a favourable safety profile as it is not systemically absorbed.[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308]
Mixtures: LIBERTRIM® SII 100 MG, BROMUX D® 100/300 MG CÁPSULA.Categories: Compounds used in a research, industrial, or household settingLevosimendan
go.drugbank.com/drugs/DB00922ApprovedInvestigationalWithdrawnLevosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels.
Categories: Heterocyclic Compounds, 1-Ring, Phosphodiesterase 3 InhibitorsProducts: SIMDAX 2.5 MG/ML KONSANTRE INF.COZ.5 ML X FLAKON, 1 ADET, DAXIM® 2.5 MG / MLAlizapride
go.drugbank.com/drugs/DB01425InvestigationalAlizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects.
Categories: Dopamine D2 Receptor Antagonists, Heterocyclic Compounds, 1-RingProducts: ALIZAPRIDA 50 MG/ 2 ML, ALIZAPRIDA SOLUCION INYECTABLE 50 MG/ 2 MLAmantadine
go.drugbank.com/drugs/DB00915ApprovedInvestigationalAn antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia.
Synonyms: 1-adamantanamine, 1-adamantylamineMixtures: ROSEL-T, Innoprax-5Tirzepatide
go.drugbank.com/drugs/DB15171ApprovedInvestigational[A246265] Tirzepatide was approved by the FDA on May 13, 2022, under the brand name MOUNJARO by the FDA for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor … Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.
Categories: Receptors, G-Protein-Coupled, GLP-1 AgonistsProducts: Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 1 ADET, Mounjaro 5 mg/0,5 ml Enjeksiyonluk Çözelti, 4 ADETAtosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalAlthough initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form.
Products: EVERPREM® SOLUCIÓN PARA INFUSIÓN 6.75 MG/0.9 ML, TRACTOCILE 7,5 MG/ML ENJEKSIYONLUK ÇÖZELTİ, 0,9 ML FLAKON, 1 ADETSemaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigationalSemaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. … Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes.
Categories: Glucagon-like peptide-1 (GLP-1) analogues, GLP-1 AgonistsProducts: WEGOVY® 2.4 MG/DOSIS (3.2 MG/ML), Wegovy® 1 mg/0.5 mL (1 mg/dose) Solution for injection in pre-filled pen